As a Med Honors Top Pharmaceutical Innovator, Amgen has been a pioneer in biotechnology since its founding in 1980. The company focuses on developing therapies for serious illnesses, with significant contributions in oncology and cardiovascular diseases. Amgen's commitment to advancing biologic treatments has led to innovative solutions that have improved patient outcomes worldwide.

In oncology, Amgen is dedicated to delivering new therapies to patients with complex cancers, where there remains significant unmet need to improve outcomes. The company is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer.

In the realm of cardiovascular diseases, Amgen has set a bold ambition to halve cardiovascular events in the U.S. by 2030. Recognizing that high levels of LDL cholesterol are a main culprit for cardiovascular events, Amgen is focusing on lowering these levels to reduce the risk of heart attack and stroke.

Amgen's dedication to scientific excellence and patient-centric innovation solidifies its position as a leader in the pharmaceutical industry and a Med Honors Top Pharmaceutical Innovator.